Q J Med 2004; 97: 115-126
QJM vol. 97 no. 3 (c) Association of Physicians 2004; all rights reserved.
Review |
Managing malignant disease in patients with porphyria
From the 1Department of Cancer Medicine, Faculty of Medicine, Imperial College London, and 2Department of Clinical Biochemistry, King's College Hospital, London, UK
Certain types of porphyria have an increased incidence of malignant disease. In addition, patients with all forms of porphyria may develop malignant disease as a normal life event. The investigation and treatment of porphyric patients with malignant disease requires specific precautions to minimize the risk of an acute porphyric attack, and to ensure optimum treatment of the malignancy. We briefly review the biochemical basis, clinical features and current management of porphyria in cancer patients.
Address correspondence to Dr C. Palmieri, Department of Cancer Medicine, 6th Floor MRC Cyclotron Building, Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 ONN. e-mail: c.palmieri{at}imperial.ac.uk